All In Biotech

Drug Trial Radar · NCT03995472

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Efficacy of SHR-1501 in Combination With SHR-1316 in Patients With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Feb 14, 2020

Primary completion

Jan 12, 2023

Study completion Jan 12, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in combination with SHR-1316 in patients with advanced malignancies and to provide a recommended dose (RP2D) for subsequent clinical studies.

Conditions

  • Advanced Malignancies

Interventions

  • SHR-1501Drug

    Administered subcutaneously

  • SHR-1316Drug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity and Maximum tolerated doseTime frame: Approximately 42 Days.
  2. Recommended Phase 2 dose (RP2D)Time frame: Approximately 2 years
  3. Adverse event/Serious adverse eventTime frame: Approximately 2 years

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Sydney Southwest Private Hospital

    Liverpool, New South Wales, Australia

  • Scientia Clinical Research

    Randwick, New South Wales, Australia

  • Icon Cancer Centre South Brisbane

    South Brisbane, Queensland, Australia

  • John Flynn Private Hospital

    Tugun, Queensland, Australia

  • Guangdong General Hospital & Guangdong Academy of Medical Sciences

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.